The medical device maker's adjusted earnings per share and revenue were more than expected, as sales of its cardiovascular products surged. Boston Scientific gave a mixed updated full-year forecast.

Bank of America Securities analyst Travis Steed maintained a Buy rating on Boston Scientific (BSX – Research Report) today. The ...

Marie Thibault, an analyst from BTIG, maintained the Buy rating on Boston Scientific (BSX – Research Report). The associated price target ...

The company should continue to benefit from market share gains for some of its products, including Watchman. Our interactive dashboard analysis of the Boston Scientific’s FY 2024Q3 Earnings ...

“We continue to gain momentum driven by our product pipeline, clinical evidence and commercial execution that position us well for the long term.” Boston Scientific increased its full-year ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions.

The company should continue to benefit from market share gains for some of its products, including Watchman. Our interactive dashboard analysis of the Boston Scientific’s FY 2024Q3 Earnings ...

Yet, with launches from J&J and Medtronic on the horizon, Needham analysts said Boston Scientific’s electrophysiology growth will slow significantly in 2025. With PFA competition set to increase, ...

Medical-products company Boston Scientific reported third-quarter results before market open Shares of Boston Scientific Corp. rose 1.1% in premarket trades Wednesday after the medical products ...

Boston Scientific , which belongs to the Zacks Medical - Products industry, posted revenues of $4.21 billion for the quarter ended September 2024, surpassing the Zacks Consensus Estimate by 4.35%.